BARRIGEL
Randomized trial of Barrigel to increase distance between the rectum and prostate bed to decrease rectal dose in patients receiving moderately hypofractionated radiation therapy who had recurrence of prostate cancer after prostatectomy
- Sex: Male
- Age: Adult (18 - 64)
- Accepting Healthy People: No
- Type: Interventional / Device
- Trial Phase: Phase IV/V
- Conditions Being Studied: Cancer - Prostate
Study Purpose
The purpose of this research is to determine if Barrigel is safe and effective (works well) when it is injected between the prostate bed and rectum to create space. The prostate bed is the location where your prostate was located previously to it being removed. This space may reduce the radiation dose and side effects to the rectum during radiation therapy treatment for prostate cancer that recurs after the prostate has been removed.
Who Can Participate
Age = 18 years
Locations
UH Cleveland Medical Center
11100 Euclid Ave
Cleveland OH, 44106
UH Seidman Cancer Center
11100 Euclid Ave
Cleveland OH, 44106
UH Ahuja Medical Center
3999 Richmond Rd
Beachwood OH, 44122
UH Beachwood Medical Center
25501 Chagrin Blvd
Beachwood OH, 44122
UH Parma Medical Center
7007 Powers Blvd
Parma OH, 44129
UH Otis Moss Jr. Health Center
8819 Quincy Ave
Cleveland OH, 44106
UH Suburban Health Center
1611 S Green Rd
South Euclid OH, 44121
- UH IRB: STUDY20250464
- StudyID: 2025-01659
- ClinicalTrials.gov: NCT06496256
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422